Format

Send to

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2009 Jul;53(7):3122-5. doi: 10.1128/AAC.00361-09. Epub 2009 May 11.

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Author information

1
Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson St., Torrance, CA 90502, USA. bspellberg@labiomed.org

Abstract

We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

PMID:
19433555
PMCID:
PMC2704638
DOI:
10.1128/AAC.00361-09
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center